Original Publication Date: 31 December, 2013
Publication / Source: CNS Oncology
Authors: Prakash Ambady, Chetan Bettegowda & Matthias Holdhoff
MRI remains the backbone of measuring disease burden and treatment response in individuals with malignant gliomas. Traditional radiographic approaches, however, are largely limited to depicting anatomic changes and are not a direct measure of disease burden. For example, contrast enhancement is related to blood–brain barrier integrity rather than actual tumor size.